This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OBLN Obalon Therapeutics (OBLN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Obalon Therapeutics Stock (NASDAQ:OBLN) 30 days 90 days 365 days Advanced Chart Get Obalon Therapeutics alerts:Sign Up Key Stats Today's Range$2.57▼$2.8550-Day Range$2.36▼$7.6452-Week Range$0.66▼$10.77Volume418,768 shsAverage Volume7.68 million shsMarket Capitalization$27.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California. Read More Receive OBLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Obalon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OBLN Stock News HeadlinesInterWest Management Partners X, LLC's Net WorthAugust 4, 2024 | benzinga.comObalon Therapeutics, Inc.February 25, 2024 | thestreet.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)Spero Therapeutics Inc.February 6, 2024 | wsj.comIntragastric Balloon Market Growth and Forecast till 2031March 28, 2023 | marketwatch.comIntragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 PagesAugust 17, 2022 | marketwatch.comRenovare Environmental Inc (RENO)January 5, 2022 | investing.comUnderstanding Atara Biotherapeutics's Unusual Options ActivityAugust 10, 2021 | benzinga.comSee More Headlines OBLN Stock Analysis - Frequently Asked Questions How were Obalon Therapeutics' earnings last quarter? Obalon Therapeutics, Inc. (NASDAQ:OBLN) issued its quarterly earnings data on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.11. The business had revenue of $0.06 million for the quarter. Obalon Therapeutics had a negative trailing twelve-month return on equity of 161.38% and a negative net margin of 776.76%. When did Obalon Therapeutics' stock split? Obalon Therapeutics shares reverse split on Thursday, July 25th 2019.The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Obalon Therapeutics IPO? Obalon Therapeutics (OBLN) raised $75 million in an IPO on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager. What other stocks do shareholders of Obalon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Canopy Growth (CGC), Plug Power (PLUG), NIO (NIO), NVIDIA (NVDA) and OPKO Health (OPK). Company Calendar Last Earnings3/11/2021Today8/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:OBLN CIK1427570 Webwww.obalon.com Phone(844) 362-2566FaxN/AEmployees2Year Founded2008Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.33 million Net Margins-776.76% Pretax MarginN/A Return on Equity-161.38% Return on Assets-83.58% Debt Debt-to-Equity RatioN/A Current Ratio1.86 Quick Ratio1.86 Sales & Book Value Annual Sales$1.59 million Price / Sales16.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book4.30Miscellaneous Outstanding Shares10,022,000Free FloatN/AMarket Cap$25.86 million OptionableNot Optionable Beta-1.23 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:OBLN) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredFuturist Eric Fry says it will be a “Summer of Surge” for these three stocksWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.